torchrelayasiangames2018| 23andMe shares surge 7.91%: Analysts maintain buy rating, target price of $2

Category:Literature Date: View:7

News summary

Medical technology stock 23andMe (MEtorchrelayasiangames2018.US) surged 7torchrelayasiangames2018.91% to US$0.55, analyst Steven Mah maintains a "buy" rating and a US$2 price target, optimistic about revenue growth and strategic advantages.

Newsletter text

Stock Morning Post: Medical and health technology stock ME.US climbed significantly before the market

torchrelayasiangames2018| 23andMe shares surge 7.91%: Analysts maintain buy rating, target price of

Shares of healthcare technology company 23andMe(ME.US) were extremely active before the market today, with shares rising from the previous trading daytorchrelayasiangames2018At 7.91%, the current quoted price per share reaches US$0.55. Steven Mah, senior analyst at TDCowen, maintained his buy recommendation on the company's stock in his latest rating report and set a price target of $2. Steven Mah believes the company's most recent quarter revenue results exceeded expectations, which is consistent with the company's strategic growth pace.

Although 23andMe's revenue fell year-on-year in the fourth quarter of last year, its final results were still better than TDCowen and Market's.torchrelayasiangames2018What his analyst expected. This result shows that the company has maintained strong revenue creation capabilities even in unfavorable market environments.

Related articles